New hope for patients with advanced, Treatment-Resistant skin cancer
NCT ID NCT05956041
Summary
This study is testing whether combining two existing cancer drugs (pembrolizumab and mogamulizumab) can help control advanced cutaneous T-cell lymphoma that has returned or stopped responding to previous treatments. The trial will enroll about 23 adults with this rare type of skin cancer who have already tried at least one other systemic therapy. Researchers will measure how many patients achieve complete disappearance of their skin lesions and how long the treatment keeps the cancer under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.